Recent studies also found that SHC1 involved in tumor microenvironment and was a promising immunotherapy target for cancer treatment (Huang et al., 2019; Carrato et al., 2020; Hu et al., 2020; Zhao et al., 2020; Yang et al., 2021). This evidence concerns the gene SHC1 and neoplasm.